X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs PANACEA BIOTECH - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD PANACEA BIOTECH BIOCON LTD/
PANACEA BIOTECH
 
P/E (TTM) x 50.9 -6.4 - View Chart
P/BV x 7.4 1.9 391.5% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 BIOCON LTD   PANACEA BIOTECH
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
PANACEA BIOTECH
Mar-14
BIOCON LTD/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,188149 798.9%   
Low Rs30582 370.6%   
Sales per share (Unadj.) Rs68.784.1 81.7%  
Earnings per share (Unadj.) Rs7.6-18.3 -41.3%  
Cash flow per share (Unadj.) Rs14.0-6.7 -208.5%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs86.383.7 103.2%  
Shares outstanding (eoy) m600.0061.25 979.6%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.91.4 791.3%   
Avg P/E ratio x98.9-6.3 -1,566.8%  
P/CF ratio (eoy) x53.4-17.2 -309.9%  
Price / Book Value ratio x8.61.4 626.6%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m447,9007,074 6,331.3%   
No. of employees `0006.12.8 223.6%   
Total wages/salary Rs m9,3111,449 642.5%   
Avg. sales/employee Rs Th6,705.81,874.1 357.8%   
Avg. wages/employee Rs Th1,514.2527.0 287.3%   
Avg. net profit/employee Rs Th736.9-407.7 -180.7%   
INCOME DATA
Net Sales Rs m41,2345,154 800.1%  
Other income Rs m2,062100 2,066.1%   
Total revenues Rs m43,2965,254 824.1%   
Gross profit Rs m8,291-766 -1,082.0%  
Depreciation Rs m3,851711 541.6%   
Interest Rs m6151,503 40.9%   
Profit before tax Rs m5,887-2,881 -204.4%   
Minority Interest Rs m21311 1,972.2%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m1,56917 9,339.3%   
Profit after tax Rs m4,531-1,121 -404.1%  
Gross profit margin %20.1-14.9 -135.2%  
Effective tax rate %26.7-0.6 -4,569.7%   
Net profit margin %11.0-21.8 -50.5%  
BALANCE SHEET DATA
Current assets Rs m41,4863,810 1,088.8%   
Current liabilities Rs m21,4138,365 256.0%   
Net working cap to sales %48.7-88.4 -55.1%  
Current ratio x1.90.5 425.4%  
Inventory Days Days64156 41.1%  
Debtors Days Days9467 140.1%  
Net fixed assets Rs m50,66114,480 349.9%   
Share capital Rs m3,00061 4,894.0%   
"Free" reserves Rs m48,808903 5,404.5%   
Net worth Rs m51,8085,127 1,010.5%   
Long term debt Rs m17,8985,832 306.9%   
Total assets Rs m99,89719,433 514.0%  
Interest coverage x10.6-0.9 -1,153.6%   
Debt to equity ratio x0.31.1 30.4%  
Sales to assets ratio x0.40.3 155.6%   
Return on assets %5.22.0 262.3%  
Return on equity %8.7-21.9 -40.0%  
Return on capital %9.63.6 264.9%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m12,0581,539 783.4%   
Fx outflow Rs m7,348942 780.0%   
Net fx Rs m4,710597 788.7%   
CASH FLOW
From Operations Rs m6,621599 1,105.0%  
From Investments Rs m-6,840-438 1,562.0%  
From Financial Activity Rs m-2,397-303 792.1%  
Net Cashflow Rs m-2,612-141 1,848.5%  

Share Holding

Indian Promoters % 40.4 74.5 54.2%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 0.6 1,400.0%  
FIIs % 10.7 1.3 823.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 23.6 84.3%  
Shareholders   109,995 10,259 1,072.2%  
Pledged promoter(s) holding % 0.0 35.1 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   VENUS REMEDIES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare BIOCON LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 150 Points Higher; Banking Stocks Witness Buying(Closing)

Indian share markets continued their momentum and ended the day on a positive note. Gains were largely seen in the banking sector, consumer durables sector and realty sector.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Dec 13, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - PIRAMAL ENTERPRISES COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS